Fennec Pharmaceuticals Inc. (TSE:FRX - Free Report) - Research analysts at HC Wainwright lifted their Q1 2025 earnings per share estimates for Fennec Pharmaceuticals in a report released on Tuesday, March 11th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings of ($0.19) per share for the quarter, up from their previous forecast of ($0.28). The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals' Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at $0.03 EPS, FY2025 earnings at ($0.40) EPS and FY2026 earnings at $0.91 EPS.
Separately, Stephens raised shares of Fennec Pharmaceuticals to a "strong-buy" rating in a report on Monday, November 18th.
Read Our Latest Report on Fennec Pharmaceuticals
Fennec Pharmaceuticals Stock Performance
Shares of FRX traded up C$0.36 on Thursday, reaching C$9.48. 207 shares of the stock traded hands, compared to its average volume of 1,501. The firm has a market cap of C$182.82 million, a price-to-earnings ratio of -160.59 and a beta of 0.25. Fennec Pharmaceuticals has a 12 month low of C$5.65 and a 12 month high of C$15.20. The stock's 50-day moving average price is C$9.21 and its 200-day moving average price is C$7.94. The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17.
Insider Buying and Selling
In other news, Director Rostislav Christov Raykov sold 7,569 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of C$9.71, for a total value of C$73,503.54. Insiders sold 21,186 shares of company stock valued at $196,017 over the last quarter. Corporate insiders own 16.20% of the company's stock.
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Read More
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
